Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Withdrawn
Phase 2

Conditions

Atherosclerotic Cardiovascular Disease

Treatments

Drug: BMS-823778
Drug: Placebo matching with BMS-823778

Study type

Interventional

Funder types

Industry

Identifiers

NCT01666704
MB121-010

Details and patient eligibility

About

The purpose of the study is to assess the effect of BMS-823778 on reducing atherosclerotic plaque inflammation

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Documented atherosclerotic cardiovascular disease or at high risk of cardiovascular event
  • On stable statin dose
  • Clinically stable at time of screening and randomization

Exclusion criteria

  • Women of child bearing potential
  • Medical conditions that would impact the absorption of the study drug

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

0 participants in 3 patient groups, including a placebo group

Treatment A: BMS-823778 (2mg)
Experimental group
Treatment:
Drug: BMS-823778
Treatment B: BMS-823778 (15mg)
Experimental group
Treatment:
Drug: BMS-823778
Treatment C: Placebo
Placebo Comparator group
Treatment:
Drug: Placebo matching with BMS-823778

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems